Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Two China Biopharmas Strike $65 Million Deal for Rights to Cell Therapy

publication date: Oct 6, 2020

Guangzhou Link Health Pharma and Shenzhen Pregene Biopharma announced a $65 million deal to acquire China/Asia rights to a cell therapy for bone fractures developed by Bone Therapeutics of Brussels. ALLOB is an allogeneic, off-the-shelf product manufactured by a proprietary process using cultured bone marrow mesenchymal stem cells from healthy adult donors. ALLOB has completed two European Phase IIa tests showing safety and efficacy. ChinaBio®, in partnership with Agile Capital, represented Bone Therapeutics in the transaction. More details....

Stock Symbol: (Euronext: BOTHE)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here